Decoy Therapeutics Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Decoy Therapeutics Inc. (DCOY) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$2.63 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-31
- Decoy Therapeutics Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$2.63M.
- Decoy Therapeutics Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2019 was -$1.46M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$2.63M 10-K · filed 2026-03-31 |
| 2019-12-31 | -$1.46M 10-K · filed 2020-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |